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Summary
Typical regimens for advanced metastatic stage IIIB/IV non-small cell lung cancer (NSCLC)
consist of multiple lines of treatment. We present an adaptive reinforcement learning approach to
discover optimal individualized treatment regimens from a specially designed clinical trial (a
“clinical reinforcement trial”) of an experimental treatment for patients with advanced NSCLC
who have not been treated previously with systemic therapy. In addition to the complexity of the
problem of selecting optimal compounds for first and second-line treatments based on prognostic
factors, another primary goal is to determine the optimal time to initiate second-line therapy, either
immediately or delayed after induction therapy, yielding the longest overall survival time. A
reinforcement learning method called Q-learning is utilized which involves learning an optimal
regimen from patient data generated from the clinical reinforcement trial. Approximating the Q-
function with time-indexed parameters can be achieved by using a modification of support vector
regression which can utilize censored data. Within this framework, a simulation study shows that
the procedure can extract optimal regimens for two lines of treatment directly from clinical data
without prior knowledge of the treatment effect mechanism. In addition, we demonstrate that the
design reliably selects the best initial time for second-line therapy while taking into account the
heterogeneity of NSCLC across patients.
Keywords
Adaptive design; Dynamic treatment regime; Individualized therapy; Multi-stage decision
problems; Non-small cell lung cancer; Personalized medicine; Q-learning; Reinforcement
learning; Support vector regression
1. Introduction
There has been significant recent research activity in developing therapies tailored to each
individual. Finding such therapies in settings involving multiple decision times is a major
challenge. For example, in treating advanced non-small cell lung cancer (NSCLC), patients
*kosorok@unc.edu.
6Supplementary Materials




Biometrics. Author manuscript; available in PMC 2012 December 1.
Published in final edited form as:













typically experience two or more lines of treatment, and many studies demonstrate that three
lines of treatment can improve survival for patients (Socinski and Stinchcombe, 2007).
Discovering tailored therapies for these patients is a very complex issue since effects of
covariates (such as prognostic factors or biomarkers) must be modeled within the multistage
structure. In this article, we present a new kind of NSCLC clinical trial, based on
reinforcement learning methods from computer science, that finds an optimal individualized
regimen at each decision time as a function of available patient prognostic information. This
new kind of trial extends and refines the “clinical reinforcement trial” concept developed in
Zhao et al. (2009) to the NSCLC setting with right-censored survival data.
For NSCLC, first-line treatment primarily consists of doublet combinations of platinum
compounds (cisplatin or carboplatin) with gemcitabine, pemetrexed, paclitaxel, or
vinorelbine (Sandler et al., 2006). These drugs modestly improve the therapeutic index of
therapy, but no combination appears to be clearly superior. More recently, the addition of
bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), to
carboplatin and paclitaxel has been shown to produce higher response rate and longer
progression-free survival and overall survival times (Sandler et al., 2006). However, this
phase III study was only designed to investigate patients with histologic evidence of non-
squamous cell lung cancer. Therefore, in first-line treatment of NSCLC, a very important
clinical question is what tailored treatment to administer based on each individual’s
prognostic factors (including e.g. patient histology type, smoking history, VEGF level, etc.).
All patients with advanced NSCLC who initially receive a platinum-based first-line
chemotherapy inevitably experience disease progression. Approximately 50–60% of patients
on recent phase III first-line trials received second-line treatment (Sandler et al., 2006).
Similar to the first-line regimen, three FDA approved second-line agents (docetaxel,
pemetrexed, and erlotinib) appear to have similar response and overall survival efficacy but
very different toxicity profiles (Ciuleanu et al., 2008; Shepherd et al., 2005). The choice of
agent should depend on a number of factors, including e.g. toxicity from previous treatments
and the risk for neutropenia. A better understanding of prognostic factors in the second-line
setting may allow clinicians to better select second-line therapy and lead to better designed
second-line trials.
The current standard treatment paradigm is to initiate second-line therapy at the time of
disease progression. Recently, two phase III trials have investigated other possible timings
of initiating second-line therapy (Fidias et al., 2007; Ciuleanu et al., 2008). Both of these
trials reveal a statistically significant improvement in progression-free survival and a trend
towards improved survival for the earlier use of second-line therapy. However, the overall
survival effect is not significant. Stinchcombe and Socinski (2008) claim that even under the
best of circumstances not all patients will benefit from early initiation of second-line
therapy. Hence, in addition to the difficulty of discovering individualized superior therapies
in second-line treatment, another primary challenge is to determine the optimal time to
initiate second-line therapy, either to receive treatment immediately after completion of
platinum-based therapy, or to delay to another time prior to disease progression, whichever
results in the largest overall survival probability.
Some patients who maintain a good performance status and tolerate therapy without
significant toxicities will receive third-line therapy (Stinchcombe and Socinski, 2008). Since
there is only one FDA approved agent (Erlotinib) available for third-line treatment, we
restrict our attention hereafter to first-line and second-line only.
Figure 1 illustrates the treatment plan and clinically relevant patient outcomes. Given the
noncurative nature of chemotherapy in advanced NSCLC, we use the overall survival time
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as the primary endpoint. The primary scientific goal of the trial is to select optimal
compounds for first and second-line treatments as well as the optimal time to initiate
second-line therapy based on prognostic factors yielding the longest average survival time.
Our design proposed in this article is based on a reinforcement learning method, called Q-
learning, for maximizing the average survival time of patients as a function of prognostic
factors, past treatment decisions, and optimal timing. Zhao et al. (2009) introduced the
clinical reinforcement trial concept based on Q-learning for discovering effective therapeutic
regimens in potentially irreversible diseases such as cancer. The concept is an extension and
melding of dynamic treatment regimes in counterfactual frameworks (Murphy, 2003;Robins,
2004) and sequential multiple assignment randomized trials (Murphy, 2005a) to
accommodate an irreversible disease state with a possible continuum of treatment options.
This treatment approach falls under the general category of personalized medicine. The
generic cancer application developed in Zhao et al. (2009) takes into account a drug’s
efficacy and toxicity simultaneously. The authors demonstrate that reinforcement learning
methodology not only captures the optimal individualized therapies successfully, but is also
able to improve longer-term outcomes by considering delayed effects of treatment. Their
approach utilizes a simple reward function structure with integer values to assess the
tradeoff between efficacy and toxicity. In the targeted NSCLC setting, however, this
simplistic approach will not work due to the choice of overall survival time as the net
reward, and new methods are required.
Our proposed clinical reinforcement trial for NSCLC involves a fair randomization of
patients among the different therapies in first and second-line treatments, as well as
randomization of second-line initiation time. This design enables estimation of optimal
individualized treatment regimes defined in counterfactual settings (cf. Murphy, 2005a).
Additionally, reinforcement learning is used to analyze the resulting data. In order to
successfully handle the complex fact of heterogeneity in treatment across individuals as well
as right-censored survival data, we modify the support vector regression (SVR) approach
(Vapnik et al., 1997) within a Q-learning framework to fit potentially nonlinear Q-functions
for each of the two decision times (before first line and before second line). In addition, a
second, confirmatory trial with a phase III structure is proposed to be conducted after this
first trial to validate the optimal individualized therapy in comparison to standard care and/
or other valid alternatives.
The remainder of this article is organized as follows. In Section 2, we provide a detailed
description of the patient outcomes and Q-learning framework, followed by the development
of a new form of SVR, ε-SVR-C, for estimating Q-functions with right-censored outcomes.
The NSCLC trial conduct and related computational issues are presented in Section 3. In
Section 4, we present a simulation study, and we close with a discussion in Section 5.
2. Reinforcement Learning Framework
2.1 Patient Outcomes
Let t1 and t2 denote the decision times for the first and second treatment lines, respectively.
After initiation of first-line chemotherapy, the time to disease progression is denoted by TP.
t2 is also the time at the completion of first-line treatment, which is a fixed value usually less
than TP and determined by the number of cycles delivered in the first line of chemotherapy.
We will assume for simplicity that TP ≥ t2 with probability 1. Denote the targeted time after
t2 of initiating second-line therapy by TM. Thus, according to the description of the treatment
plan in Section 1, the actual time to initiate the second line is (t2 + TM ) ∧ TP, and the gap
between the end of the first line and the beginning of the second line is TM ∧ (TP − t2),
where ∧ denotes minimum. At the end of first-line therapy, t2, clinicians make a decision
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about the target start time TM. We let TD denote the time of death from the start of therapy
(t1), i.e., the overall survival time, truncated if needed at the maximum follow-up time τ.
Because of the possibility of right censoring, we denote the patient’s censoring time by C
and the indicator of censoring by δ = I(TD ≤ C). We will assume for now, however, that
censoring is independent of both the death time and the patient covariates, as is often
realistic when patients are approximately similar across accrual time and censoring is due
primarily to administrative reasons. For convenience, we let T1 = TD ∧ t2 and YD = I(TD ∧ C
≥ t2), and denote T2 = (TD − t2)I(TD ≥ t2) = (TD − t2)I(T1 = t2) and C2 = (C − t2)I(C ≥ t2).
Note that TD = T1 + T2, where T1 is the years of life lived in [t1, t2] and T2 is the years of
live lived after t2. We can also define the total follow-up time T0 = TD ∧ C = T1 ∧ C + YD(T2
∧ C2).
Denote patient covariate values at the ith decision time by Oi = (Oi1, …, Oiq) for i = 1, 2.
Such covariates can include prognostic variables or biomarkers thought to be related to
outcome. In first-line therapy, we assume that the death time T1 depends on the covariates
O1 and possible treatment D1 according to a distribution [T1 | O1, D1] ~ f1(O1, D1; α1),
where decision D1 only consists of a finite set of agents d1. If the patient survives long
enough to be treated by second-line therapy, we assume that the disease progression time TP
is ≥ t2 and follows another distribution [TP | O1, D1] ~ f2(O1, D1; α2). In addition, to account
for the effects of initial timing of second-line therapy on survival, T2 given TD ≥ t2 is then
given by [T2 | O2, D1, D2, TM] ~ f3(O2, D1, D2, TM; α3), where D2 consists of a finite set of
agents d2 and TM is a continuous initiation time. We assume also that P(TD = t2) = 0. Note
that because of the independence of censoring, conditioning T2 on YD = 1 is the same as
conditioning on TD ≥ t2. Note that this study is designed to identify the initiation time, TM,
which is associated with the best combination of treatments d1 and d2, while maintaining
longest survival TD. Due to heterogeneities among patients, biomarker-treatment
interactions, and the large number of possible shapes of T2 as functions of TM, the
distributions f1, f2, and f3 can be complicated and may vary between different groups of
patients. Thus, incorporating Oi into models for fi (i = 1, 2, 3) is quite challenging, and such
model-based approaches can easily become intractable (Thall et al., 2007). Another
important issue is accounting for delayed effects. Thall et al. (2007) claimed that
conventional model-based approaches cannot handle this kind of situation very well. Based
on clinical data, reinforcement learning is not only a model-free method which carries out
treatment selection sequentially with time-dependent outcomes to determine optimal
individualized therapy, but it can also improve longer-term outcomes by incorporating
delayed effects.
2.2 Q-Learning Framework
We will utilize a Q-learning framework (Watkins, 1989), one of the most widely used
reinforcement learning methods, for our approach because Q-learning directly facilitates the
necessary modeling, estimation and optimization in our setting. In a multi-stage decision
problem, with T decision times, if we denote each decision point by t, state St, action At, and
incremental reward Rt, t = 1, …, T, are three fundamental elements of Q-learning. In the
clinical setting, the meaning of state, action, and reward could be defined respectively as
patient covariates and treatment history, treatment options and timing, and survival time, for
example. Q-learning assigns values to action-state pairs, and it is learning, based on St, how
best to choose At to maximize the expected sum R̄t = r1 + ··· + rT of the incremental rewards.
The algorithm has a so-called Q function which calculates the quality of a state-action
combination as follows: Q: S × A → ℝ. The motivation of Q-learning is that once the Q
functions have been estimated, we only need to know the state to determine an optimal
action, without the knowledge of a transition model that tells us what state we might go to
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next. The core of the algorithm results from the definition of the Q function and a simple
value iteration update. The Q function at time t, given state St = st and action At = at, is the
expectation of the sum of the incremental reward Rt = rt and all future incremental rewards
under the assumption that the optimal course of action will be taken at all decision times
greater than t: t+1, …, T. This structure yields the recursive identity (Murphy, 2005b)
(1)
The Q-learning algorithm attempts to find a policy π (i.e., a regimen in our clinical trial
setting) that maps states to actions the learner ought to take in those states. π is possibly
deterministic, non-stationary, and non-Markovian. We denote the optimal policy at time t by
, which satisfies: .
Zhao et al. (2009) performed a simulation study of a simple Q-learning approach with 6
decision time points for discovering optimal dosing for treatment of a simplistic generic
cancer. While the results were encouraging, much work remained before these methods
could be applied to specific, realistic cancer scenarios, such as the NSCLC setting of this
paper. For example, in their study, the choice of treatments at each decision time point is
taken simply among a continuum of dosing levels. However, in NSCLC treatment with two
decision time points, the action variables in the second stage become two-dimensional (d2
and TM ). The second issue is that overall survival time, the endpoint of interest in NSCLC,
cannot be utilized in the usual reward function structure in standard Q-learning, and new
methodology and modeling are needed. Moreover, the presence of censoring in the reward
outcome means that a fundamentally new approach for estimating the Q-function is needed.
In reinforcement learning, the state variable at a given time point could be defined as current
and historical prognostic information, including both observations and actions prior to that
time. In our clinical setting, we respectively denote the state and action random variables by
Oi and Di for i = 1, 2, since there are only two decision times in our setting. This is
consistent with the notation used in Section 2.1. Denoting O2 as the state variable at t2
means we make an assumption that the next action selection only depends on patient
covariate values at t2. This is a working assumption for model building but is not in general
true since the state of a patient at time ti technically contains all historical information
available up to and including time ti. As mentioned in Section 1, we consider overall
survival time TD = T1 + T2 as the total reward. Specifically, by performing a treatment d1,
where d1 ∈ D1, the patient can transit from first line to second line treatment. This treatment
associated with prognostic factors provides the patient a progression time TP and T1.
Moreover, D2, which consists of two dimensional action variables consisting of both a
discrete action (agent) d2 combined with a continuous action (time) TM, provides the patient
a survival time T2 given TD ≥ t2. The incremental reward function for the first stage is T1 ~
G1(o1, d1). In the second stage, the incremental reward function is T2, where T2 satisfies T2
~ G2(o2, d1, d2, TM ). Functions G1 and G2 are obtainable from f1 and f3, defined previously,
and are usually not observable. Note also that both T1 and T2 are censored rather than
directly observed. In Q-learning, because for every state there are a number of possible
treatments that could be taken, each treatment within each state has a value according to
how long the patient will survive due to completion of that treatment. The scientific goal of
our study is to find an optimal regimen to maximize overall patient survival time TD (in
practice, we maximize restricted mean survival). Thus our reward function is TD ∧ τ, since
we cannot observe any events beyond the maximum follow-up time τ.
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While learning a non-stationary non-Markovian optimal regimen from a clinical
reinforcement trial data set (given TD ∧ C ≥ t2), where observations consist of {O1, D1, T1 ∧
C, O2, D2, T2 ∧ C2}, we denote the estimate of the optimal Q-functions based on this
training data by Qt(θ ̂t), where t = 1, 2, 3. The indices 1 and 2 correspond to the decision
times t1 and t2 while index 3 is included only for mathematical convenience. According to
the recursive form of Q-learning in (1), we must estimate Qt backwards through time, that is,
use the estimate Q3 from the last time point back to Q1 at the beginning of the trial. For
convenience we set Q3 equal to 0. In order to estimate each Qt, we denote Qt(Ot, Dt; θt) as a
function of a set of parameters θt, and we allow the estimator to have different parameter
sets for different time points t. Once this backwards estimation process is done, we save
Q1(θ ̂1) and Q2(θ ̂2), and we thereafter use them to respectively estimate optimal treatment
policies π̂1 = argmaxd1 Q1(o1, d1; θ ̂1) and π̂2 = argmaxd2,TM Q2(o2, d2, TM; θ ̂2), for new
patients. Since the resulting estimated optimal policies are functions of patient covariates,
the resulting treatment regimens are individualized. These individualized treatment regimens
should also be evaluated in a follow-up confirmatory phase III trial comparing the optimal
regimens with the standard care or other appropriate fixed (i.e., non-individualized)
treatments.
In a counterfactual framework, optimal treatment regimes are defined via potential
outcomes. In the Web Appendix A, we show that under the proposed sequential
randomization design, the obtained optimal treatment policies (π̂1, π̂2) based on the
empirical observations are actually the correct estimates of the optimal treatment regimes in
the counterfactual framework.
2.3 Support Vector Regression for Censored Subjects
A strength of Q-learning is that it is able to compare the expected reward for the available
treatments without requiring a model of the relationship. To achieve this, the main task is to
estimate the Q functions for finding the corresponding optimal policy. However, challenges
may arise due to the complexity of the structure of the true Q function, specifically, the non-
smooth maximization operator in the recursive equation (1). Nonparametric statistical
methods are appealing for estimating Q functions due to their robustness and flexibility. For
instance, using random forest (RF) or extremely randomized trees (ERT) techniques is very
effective for extracting well-fitted Q functions (Ernst, Geurts, and Wehenkel, 2005; Geurts,
Ernst, and Wehenkel, 2006; Guez, Vincent, Avoli, and Pineau, 2008; Zhao et al., 2009).
Besides the RF and ERT methods, other methodologies for fitting Q include, but are not
limited to, neural networks, kernel-based regression (Ormoneit and Sen, 2002), and support
vector machines (SVM) (Vapnik, 1995). Our experience so far indicates that both SVR and
ERT work quite well and their accuracy is approximately equivalent, although ERT is more
computationally intense (Zhao et al., 2009).
In the present article we apply SVR as our main method to fit Q functions and learn optimal
policies using a training data set. The ideas underlying SVR are similar but slightly different
from SVM within the margin-based classification scheme. To illustrate, consider the case
where the rewards in the training data set are not censored. At each stage, given ,
where attributes xi ∈ ℝm and label index yi ∈ ℝ, the goal in SVR is to find a function f: ℝm
→ ℝ that closely matches the target yi for the corresponding xi. Note that in our simulation
study in Section 4, xi may be replaced by information of states along with actions and yi may
be replaced by survival time, respectively. Instead of the hinge loss function used in SVM,
one of the popular loss functions involved in SVR is known as the ε-insensitive loss function
(Vapnik, 1995), which is defined as: L(f(xi), yi) = (|f(xi) − yi| − ε)+, where ε > 0 and the
subscript + denotes taking the positive part. That is, as long as the absolute difference
between the actual and the predicted values is less than ε, the empirical loss is zero,
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otherwise there is a cost which grows linearly. Here L(f(xi), yi) is a loss used in estimation
and bears no relation to the reward function described in previous sections. SVR is more
general and flexible than least-squares regression, since it allows a predicted function that
has at most ε deviation from the actually obtained targets yi for all the training data.
Unfortunately, this approach as is cannot be implemented in the presence of censoring.
In general, we denote interval censored data by . If the patient experiences the
death event and TD is observed rather than being interval censored then we include TD and
denote such an observation by (xi, yi). When we observe TD exactly (δ = 1), we let li = ui =
yi. Note that by letting ui = +∞ we can easily construct a right censored observation (xi, li,
+∞).
One naive way to handle censored data within Q-learning by using SVR is to consider only
those samples for which the survival times TD are known exactly. Such an approach which
totally ignores censoring will both reduce and bias the sample for statistical analysis and
inference. An SVR procedure that targets interval censored subjects was introduced by
Shivaswamy, Chu, and Jansche (2007). The key component of their procedure is a loss
function, defined as L(f(xi), li, ui) = max(li − f(xi), f(xi) − ui)+. However, this loss function
does not have ε-insensitive properties, that is, it does not allow ε or other deviations from the
predicted f(xi), especially when li = ui = yi. In this article, we propose a modified SVR
algorithm with ε-insensitive loss function (called ε-SVR-C) which can be applied to
censored data.
Given the interval censored data set , our modified loss function is defined as
We remark that this loss function does not penalize the value of f(xi) if it is between li − ε
and ui + ε. On the other hand, the cost grows linearly if this output is more than ui + ε or less
than li − ε. Figure 2 shows the loss function of the modified SVR. Note that when ui = +∞,
this loss function becomes one sided, which means there is no empirical error if f(xi) ≥ li −
ε. In addition, when the data is not censored, our modified SVR algorithm reduces to the
classical SVR. Defining index sets L = {i: li > −∞} and U = {i: ui < +∞}, the ε-SVR-C
optimization formulation is:
(2)
Here, wTΦ(xi)+b is the separating hyperplane, where Φ is a nonlinear transformation which
maps data into a feature space. ξi and  are slack variables and CE is the cost of error. By
minimizing the regularization term  as well as the training error ,
ε-SVR-C can avoid both overfitting and underfitting of the training data. A class of
functions called kernels K: ℝm × ℝm → ℝ such that K(xi, xj) = Φ(xi)TΦ(xj) (for example, the
Gaussian kernel is K(xi, xj) = exp (−ζ||xi − xj||2)) are used in ε-SVR-C to guarantee that any
data set becomes arbitrarily separable as the data dimension grows. Since the ε-SVR-C
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function is derived within this reproducing kernel Hilbert space (RKHS) context, the explicit
knowledge of both Φ and w are not needed if we have information regarding K. In this case,
problem (2) is equivalent to solving the following optimization dual problem:
Both parameters ζ and CE in ε-SVR-C are obtained by utilizing cross validation to achieve
good performance. Once the above formulation is solved to get the optimal λi and , the
approximating function at x is given by: .
3. Trial Conduct and Computational Strategy
We will now describe a virtual clinical reinforcement trial which provides a realistic
approximation to a potentially real NSCLC trial that evaluates two-line regimens for patients
with NSCLC who have not been treated previously with systemic therapy. As mentioned in
Section 1, while many new single agents with potential clinical efficacy currently are being
produced at an increasing rate, the number of doublet combinations in the first line that can
be evaluated clinically is limited. Considering the number of possible agents that may be of
interest in the second line, the limitations are even greater.
Without loss of generality, suppose for simplicity that regimens are based on four FDA
approved therapies (either single agents or doublets), which we denote by Ai, i = 1, …, 4. In
our study we assume that the second line treatment must be different from the first. Two of
the four agents A1 and A2 are restricted to first-line treatment, while A3 and A4 are restricted
to second line. A total of N patients are recruited into the trial and fairly randomized at
enrollment between A1 and A2, and each patient is followed through to completion of first-
line treatment, given the patient is not dead or lost to follow-up from the study. We fix this
duration t2 − t1 at 2.8 months, although other lengths are possible, depending on the number
of cycles of treatment. At the end of first-line treatment, patients are randomized again
between agents A3 and A4 and also randomized to treatment initiation time. This will be
accomplished by randomizing to a target initiation time TM over the interval [0, 2] (in
months) and then initiating second line therapy at TM ∧ (TP − t2). At the end of the trial, the
patient data is collected and Q-learning is applied, in combination with SVR applied at each
time point, to estimate the optimal treatment rule as a function of patient variables and
biomarkers, at t1 and t2.
The trial described above was motivated by the desire to compare several agents as well as
timing in a randomized fashion, the belief that different agents combined with different
timing given consecutively may have different effects for different populations of patients,
and the desire to determine a sound basis for selecting individualized optimal regimens for
evaluation in a future clinical trial. Putting this all together, the entire algorithm for Q-
function estimation and optimal treatment discovery can be summarized as follows:
1. Inputs: Each of n observed individual will have an initial (time t1) set of attributes
x1 = (o1, d1) and index y1 = (T1 ∧ C, δ1 = I{T1 ≤ C}); and, if YD = 1, they will also
have time t2 observations x2 = (o2, d2, TM) and y2 = (T2 ∧ C2, δ2 = I{T2 ≤ C2}).
2. Initialization: Let Q3 be a function equal to zero.
3. Q2 is fitted with ε-SVR-C through the following equation: Q2(o2, d2, TM) = T2 +
error, where T2 is assessed through the censored observation {T2 ∧ C2, δ2}. This is
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possible to do since we are restricting ourselves in this step to patients for whom YD
= 1. In other words, for those individuals with YD = 1, we perform right-censored
regression using ε-SVR-C of (T2 ∧ C2, δ2) on (o2, d2) to obtain Q ̂2.
4. Q1 is fitted with ε-SVR-C through the following equation:
where T1 + I(T1 = t2)T ̂2 is assessed through the censored observation (X̃, δ̃), with X̃
= T1 ∧ C + YDT ̂2. The reason this works can be summarized in two steps: First, we
can show after some algebra that X̃ = T ̂D ∧ C̃ and δ̃ = I(T ̂D ≤ C̃), where T ̂D = T1 +
I(T1 = t2)T ̂2 and C̃ = CI(C < t2) + ∞I(C ≥ t2), and thus we have independent right
censoring of the quantity T ̂D. Second, since Q1 needs to model the expectation of
TD given the covariates (O1, D1) under the assumption that the optimal choice is
made at the second decision time, it is appropriate that we replace TD with the
quantity T1 + I(T1 = t2)T ̂2, since T ̂2 estimates E maxd2,TM E(T2 |O1, D1, TD ≥ t2, O2,
d2, TM). In summary, we perform regression using ε-SVR-C of (X̂, δ̃) on (o1, d1) to
obtain Q ̂1.
5. For the SVR computations in steps 3 and 4, we use a Gaussian kernel with a
straightforward coarse grid search over CE = 2−5, 2−3, …, 215 and ζ = 2−15, 2−13,
…, 23, and then select the pair (CE, ζ) that yields the highest cross-validated rate of
correctly classifying the data.
6. Given Q1(θ ̂1) and Q2(θ ̂2), we compute the optimal polices π̂1 and π̂2.
4. Simulation Study
To demonstrate that the tailored therapy for NSCLC found by using the proposed clinical
reinforcement trial is superior, we employ an extensive simulation study to assess the
proposed approach on virtual clinical reinforcement trials of patients, and then evaluate
using phase III trial-like comparisons between the estimated optimal and various possible
fixed treatments.
4.1 Data Generating Models
Based on historical research, it is well known that the rate of disease progression or death for
patients with advanced NSCLC is non-decreasing over time. Consequently, in order to
generate simulated data, we simply consider that T1, TP − t2, and T2 conditional on TD ≥ t2
follow different exponential distributions. Many alternative models are also possible.
Let exp(x) denote an exponential distribution with mean ex. Also let Wt and Mt be patient
prognostic factors observable at t = 1, 2 (corresponding to times t1 and t2) to be defined
shortly. For a patient given first-line treatment d1, we assume that T1 = T ̃1 ∧ t2, where
(3)
If T ̃1 ≥ t2, we generate TM from a uniform [0, 2] distribution. We now absorb TP into TM for
modeling T2 given TD ≥ t2 through an intent-to-treat structure (basically, we can ignore TP
since it depends only on D1, M1 and W1 and not on TM). In addition, for a patient given
second-line treatment d2 and initiation time TM, we assume
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where h(TM; ϕ) is a function depending on the parameter ϕ which reflects the effect of
timing TM on death. The shape of this time-related function may vary among different
patients because of its dependence on patient characteristics. The total time to death is then
TD = T1 + I(T1 = t2)T2. τ is set to 25 (months). We then need to generate the right censoring
time C uniformly from the interval [t1, t1 + u]. To find u, we estimate the unconditional
survival function Ŝ(t) for the failure time TD, where “unconditional” refers to taking
expectation over the covariates Di, Wi, Mi(i = 1, 2), and TM of the conditional survival
function TD. Then, u is the solution to , where p is the desired probability
of censoring.
Note that in our simulation study we straightforwardly use exponential pdfs (3) and (4) to
replace f1 and f3 and we drop f2, where (f1, f2, f3) were described in Section 2.1. For the sake
of simplicity, in these density functions only two state variables, quality of life (QOL) Wt
and tumor size Mt, are considered as patient prognostic factors or biomarkers to be related to
outcome. We consider these two factors because they are patient based, realistically easy to
measure, can predict therapeutic benefit after treatment of chemotherapy, and, more
importantly, they are significant prognostic factors for survival (Socinski et al., 2007). In
addition, state variables for the next decision are generated by the simple dynamic models
W2 = W1 + TM Ẇ1 and M2 = M1 + TM Ṁ1, where Ẇ1 and Ṁ1 are constants.
The parameter vector for those receiving only first-line treatment is θ1 = (αD1, βD1, κD1,
τD1), otherwise it is . Note that two patients receiving
different second-line treatments, say (A1, A3) and (A1, A4), both contribute data for
estimating Q1.
4.2 Clinical Scenarios
To construct a set of scenarios reflecting interaction between lines of treatment, we
temporarily assume that a large portion of patients survive long enough to be treated by
second-line therapy, that is, we adjust the parameters so that P(YD = 1) = 0.8 averaged
across all patients. Other than the constraint on P(YD = 1), each clinical scenario under
which we will evaluate the design in the simulation study is built by a unique set of fixed
values of ( , αD12, βD12, κD12). The remaining fixed parameter values needed
for the simulations are those that determine how T2 varies as a function of TM. To implement
this, we specified four different cases for the function h(TM; ϕ).
The four resulting scenarios are specified and summarized in Table 1. In group 1 and 4,
initial timing of second-line therapy for survival time (T2) are functions that form an
inverse-U (quadratic) shape with TM, while initial timing in group 2 and 3 for T2 are
functions that linearly decrease and increase with TM, respectively. Each group thus consists
of a combination (Ai, Aj) as well as TM from Table 1 (where i = 1, 2 and j = 3, 4), with the
fixed values of , αD12, βD12, κD12, and ϕ as described above.
Note that whatever combination of two-line treatment (Ai, Aj) is evaluated, all patients
within one group share the same trend of T2 versus TM. However, we assume there is only
one regimen that will yield the longest survival in each group. For convenience, we denote
“1, 2, 3” as the location of optimal initiation of second-line therapy, corresponding to
“immediate, intermediate, and delayed”, respectively. For example, as claimed in the last
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column in Table 1, A1A32 indicates that the two-line treatments (A1, A3) along with an
intermediate initiation time point is the optimal regimen for group 1. The inverse-U-shaped
function for T2 versus TM corresponds to the case where patients have relatively low QOL at
enrollment but relatively large tumor size, hence, this optimal intermediate initiation of
second-line therapy is recommended to delay treatment a short time for patients who may
have severe symptoms and low tolerance of chemotherapy, but not to fully delay due to the
need to treat the cancer. In scenario 2, due to the good QOL and large tumor size at
enrollment, it is optimal for the second-line therapy to begin immediately after first-line
therapy, hence, A1A41 is the optimal regimen for these patients. Similarly, in scenario 3,
treatment A2A33 is considered the superior treatment since we believe fully that delaying the
initiation of second-line therapy at the time of disease progression will improve survival and
palliate symptoms. Although scenario 4 has optimal regimen A2A42, due to the flat shape of
T2 versus TM, there is no significant improvement between delaying and not delaying the
initiation of second-line therapy. In this manner, many plausible effects of treatment are
captured, at least to some degree, including both reversible and irreversible toxicities
resulting from chemotherapy.
4.3 Simulation Methods and Results
First, according to various (W1, M1) as described in Table 1, a non-censored sample of N =
100 virtual patients for each of the four disease profile groups (with total sample size n =
400) is generated. Q1(θ ̂1) and Q2(θ ̂2) are computed via the algorithm given in Section 3
(since the method is robust to the choices of relatively small value of ε, ε is set to 0.1). The
predicted optimal regimens are then computed, and an independent testing sample of size
100 per disease profile group (hence also totaling 400) is also generated. For evaluation
purposes, we then assign all virtual test patients to all possible combinations of (Ai, Aj) ×
{immediate, intermediate, delayed} as well as the estimated optimal regimen, resulting in 13
possible treatments. Patients outcomes (overall survival) resulting from our estimated
optimal regimen and the 12 different fixed regimens are all evaluated. This is similar in
spirit to a virtual phase III trial with 5200 = 13 × 400 patients, except that the estimated
effects will be more precise. Moreover, we repeated the simulations 10 times for the training
sample trial (each trial having sample size n = 400). Then, 10 estimated optimal regimens
learned from these 10 training trials were applied to the same test patients described above.
All of the results for each of the 13 treatments are averaged over the 400 test patients. This is
initially done with uncensored data using SVR to fit the Q-functions. We will later evaluate
the effect of censoring using our proposed ε-SVR-C.
As shown in Figure 3, among regular regimens, assigning all test patients to A2A32 will
yield the averaged longest survival among the 12 fixed treatments at 11.29 months. It thus
appears that, in terms of adaptively selecting the best regimen for each group, the optimal
regimen obtained by Q-learning with SVR is superior due to its average (over 10
simulations) survival of 17.48 months. The survival curves for the groups (based on the
Kaplan-Meier estimates) are shown in Figure 4, which demonstrates the effectiveness of the
proposed approach for prolonging survival. Because of this encouraging result, it is
worthwhile to deeply investigate whether our approximations are close to the exact solution.
To carefully examine this comparison, we assign test patients from each disease profile
group to the corresponding true optimal regimen described in Table 1 to obtain the “True
survival” column of Table 2. The minimum, maximum, and mean values of averaged
predicted survival for each group are computed based on these 10 trials, respectively. The
results are summarized in Table 2. The averaged predicted survival over all groups is shown
as 17.48 (which is consistent with the number shown below the “optimal” bar in Figure 3),
this number along with the minimum 17.28 and the maximum 17.63 are all pretty close to
the true optimal survival 17.61. In addition, the averaged selected optimal timings are shown
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in the fifth column of Table 2. Note that they are close to true optimal timings for each
group. In terms of estimation, under each of the scenarios 1–3 our method performs very
similarly and slightly underestimates the true optimal survival. In contrast, our method
slightly overestimates the true optimal survival in scenario 4.
Second, although our Q-learning method with N = 100 per group using SVR leads to an
apparently small bias for estimating individualized optimal regimens, an examination of
performance influenced by the sample size is worthwhile. We repeated the simulations 10
times for each specified sample size while varying N from 2 to 600 per group. The results
are illustrated in Figure 5, which shows that the method’s reliability is very sensitive to N
when N ≤ 80, with the averaged survival for the estimated optimal regimen increasing from
14.192 when N = 2 to 17.479 when N = 80. The boxplots also show that both the variance
and estimation bias of predicted survival become smaller when the sample size becomes
larger. When N ≥ 100, our methods appear to do a very reliable job of selecting the best
regimen. Hence, in the setting we study here, the sample sizes required to reach an excellent
approximation are similar to the sizes required for typical phase III trials.
Third, in order to compare performance of ε-SVR-C for censored subjects to ignoring the
censored cases and using SVR, from 400 training samples in each simulated trial, we
randomly censor as described in Section 4.1 to achieve a targeted proportion of censoring p,
estimate the optimal treatment regimen using ε-SVR-C, throw out the censored observations
and use SVR to estimate the optimal regimen, and then apply 400 test patients to the
estimated regimens to estimate the restricted mean survival. This is done for 25%, 50%, and
75% censoring proportions p, respectively. The boxplots are presented in Figure 6. For
instance, in panel (a) we generate 10 training trials with 25% censoring. The dotted line
going through two boxplots indicates the performance for the true optimal regimen without
any censoring but with maximum possible follow-up truncation. The left boxplot indicates
the performance based on ε-SVR-C applied to the 25% censored data, while, in the right
boxplot, we simply delete the 25% of patients which are right-censored and apply SVR to
the remaining data to estimate the optimal regimen. This basic process is repeated across the
three different censoring levels. As can be observed in Figure 6, as the fraction of right-
censoring increases, there is an increasing decline in performance resulting from throwing
out censored observations. In contrast, our proposed approach (the left boxplot of each
panel) can robustly estimate the optimal regimen under censoring, with only a minor
increase in bias as censoring increases. Clearly, in terms of averaged predicted survival in all
cases, the ε-SVR-C algorithm outperforms the method which totally ignores the censored
data, particularly when the censoring proportion is large.
5. Discussion
We have proposed a clinical reinforcement trial design for discovering individualized
therapy for multiple lines of treatment in a group of patients with advanced NSCLC. The
incorporation of Q-learning with the proposed ε-SVR-C appears to successfully identify
optimal regimens tailored to appropriate subpopulations of patients. We believe in general
that Q-functions in clinical applications will be too complex for parametric regression and
that semiparametric and nonparametric regression approaches, such as ε-SVR-C, will be
needed. While our method has been utilized for the two decision points at hand, the general
concepts and algorithms of this approach could be applied to design future trials having
similar goals but for possibly different diseases. Although overall survival time is considered
among many clinicians to be the appropriate primary endpoint in late stage NSCLC, a
potentially important alternative outcome to consider is quality-of-life-adjusted survival
(Gelber et al., 1995). This may require some modification of the proposed ε-SVR-C
methodology.
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An important point to make is that the primary goal of the proposed Q-learning approach is
to obtain optimal treatments that are reproducible. Thus our first goals is to ensure that our
operating characteristics are such that optimal, or nearly-optimal, treatments can be
consistently and reproducibly identified with our proposed method. We believe that we have
demonstrated this in this paper. An important next step in the research process is to obtain
more refined statistical inference for our proposed approach, including confidence sets for
the resulting treatment regimens and associated Q-functions. This is an area of active,
ongoing work, which we are pursuing. In this article, we studied the prediction accuracy of
our method with varying sample sizes. The simulation studies show that with sample size N
≥ 100 our method can yield a small estimation bias. Thus, another important and
challenging question is: how do we determine an appropriate sample size for a clinical
reinforcement trial to reliably obtain a treatment regimen that is very close to the true
optimal regimen? This sample size calculation is related to the statistical learning error
problem. Recently, there has been considerable interest in studying the generalization error
for Q-learning. Murphy (2005b) derived finite sample upper bounds in a closely related
setting which depends on the number of observations in the training set, the number of
decision points, the performance of the approximation on the training set, and the
complexity of the approximation space. We believe further development of this theory is
needed to better understand how performance of Q-learning with SVR is related to sample
size of the training data in clinical reinforcement trials. We hope that this article will serve to
stimulate interest in these issues.
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Treatment plan and therapy options for an advanced NSCLC trial.
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Modified SVR loss functions for interval censored data (a) and right censored data (b).
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Performance of optimal individualized regimen versus other 12 combinations. The numbers
above the regimens (12 possible combinations and the optimal regimen) indicate the
estimated average survival times for each regimen.
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Survival functions for testing sample treated by 13 different regimens (12 fixed treatments
plus optimal regimen).
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Sensitivity of the predicted survival to the sample size.
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Boxplots of the estimated mean restricted survival for the optimal regimen, estimated from a
training sample of 400 observations. The boxplots are data summaries over 10 simulation
replicates. Results are presented for ε-SVR-C and for the naive SVR analysis that discards
the censored observations, with censoring levels of (a) 25%, (b) 50% and (c) 75%. The
dotted line represents the true mean restricted survival for the optimal regimen.
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Table 1
The scenarios studied in the simulation. Sample size = 100/group.
Group State Variables Status Timing (h) Optimal Regimen
1
W1 ~ N (0.25, σ2)
M1 ~ N (0.75, σ2) W1 ↓ M1 ↑ A1A32
2
W1 ~ N (0.75, σ2)
M1 ~ N (0.75, σ2) W1 ↑ M1 ↑ A1A41
3
W1 ~ N (0.25, σ2)
M1 ~ N (0.25, σ2) W1 ↓ M1 ↓ A2A33
4
W1 ~ N (0.75, σ2)
M1 ~ N (0.25, σ2) W1 ↑ M1 ↓ A2A42
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